Seoul National University Pituitary Disease Cohort Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03474601

Acronym

SNU-PIT

Enrollment

1600

Registered

2018-03-22

Start date

2015-03-15

Completion date

2025-02-14

Last updated

2020-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly, Central Diabetes Insipidus, Cushing's Disease, Pituitary Disease, Pituitary Incidentaloma, Pituitary Stalk Compression Hyperprolactinaemia, Pituitary Tumor, Prolactinoma

Keywords

Pituitary Diseases, Pituitary incidentaloma, Central Diabetes Insipidus, Pituitary Neoplasms

Brief summary

The purpose of this study is to investigate the treatment and natural history of pituitary disease. We have a longstanding interest in pituitary disease including acromegaly, central diabetes insipidus, and nonfunctioning pituitary adenoma. We will continue to follow patients and recruit new patients for treatment and follow-up. Blood and pituitary tumor tissue (when available through clinical care) will be saved for future analyses related to pituitary disease.

Detailed description

Subjects for this study will be recruited if they are: 1. Adults, male or female aged 18 years or older 2. Have been diagnosed with pituitary diseases

Interventions

OTHERDynamic hormone study and Magnetic resonance imaging

1. Medical history 2. Imaging examination including brain magnetic resonance imaging 3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects for this study will be recruited if they are: 1. Adults, male or female aged 18 years or older 2. diagnosed with pituitary diseases such as acromegaly, Cushing's disease, hyperprolactinemia, nonfunctioning pituitary adenoma, pituitary stalk lesions, central diabetes insipidus, and craniopharyngiomas

Exclusion criteria

* Patients who do not agree with the study

Design outcomes

Primary

Measure	Time frame	Description
Treatment outcome of pituitary diseases	Up to 10 years	Remission rate

Secondary

Measure	Time frame	Description
Complications of pituitary disease	Up to 10 years	Visual field defect or hypopituitarism, hormone hyperfunction-related complications

Countries

South Korea

Contacts

Primary ContactJung Hee Kim, M.D

jhkxingfu@gmail.com82-2-2072-4073

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026